NovoCure (NVCR) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- —
- Estimate
- -$0.23
- Surprise
- —
- Score today
- 5.7/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- NovoCure Q3 2026 Earnings Call Transcript — benzinga, 2026-10-29
- NovoCure Q3 EPS $(0.09) Beats $(0.24) Estimate, Sales $193.399M Beat $182.233M Estimate — benzinga, 2026-10-29
- NovoCure Raises FY2026 Sales Guidance from $710.000M-$725.000M to $736.000M-$743.000M vs $725.814M Est — benzinga, 2026-10-29
Where TrendMatrix's rating stands now
TrendMatrix currently rates NVCR Sell at 5.7/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate.
What argues against it
- Concentration risk — Product: Optune Gio (glioblastoma)
- Quality below floor (4.0 < 4.0)
- Momentum score 2.1/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $12.83
- Price target
- $23.37
- Stop
- $11.93
- Upside to target
- +82.2%
- Reward-to-risk
- 6.8:1
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
NVCR at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $1.65B
- P/E (fwd)
- -17.6
- 52-week range
- $9.82–$21.45
- Off 52-week high
- 40.2%
- RSI (14)
- 37
- Volume vs avg
- 0.67×
- Score today
- 5.7/10